0001623082-24-000005.txt : 20241101
0001623082-24-000005.hdr.sgml : 20241101
20241101152034
ACCESSION NUMBER: 0001623082-24-000005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20241030
FILED AS OF DATE: 20241101
DATE AS OF CHANGE: 20241101
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SALAMON STEVEN A J
CENTRAL INDEX KEY: 0001623082
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16133
FILM NUMBER: 241418776
MAIL ADDRESS:
STREET 1: 15 WELLESLEY STREET WEST, SUITE 326
CITY: TORONTO
STATE: A6
ZIP: M4Y 0G7
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC.
CENTRAL INDEX KEY: 0000872912
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 061245881
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 566 QUEENSBURY AVENUE
CITY: QUEENSBURY
STATE: NY
ZIP: 12804
BUSINESS PHONE: (518) 743-8892
MAIL ADDRESS:
STREET 1: 566 QUEENSBURY AVENUE
CITY: QUEENSBURY
STATE: NY
ZIP: 12804
FORMER COMPANY:
FORMER CONFORMED NAME: DELCATH SYSTEMS INC
DATE OF NAME CHANGE: 19990607
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-10-30
0
0000872912
DELCATH SYSTEMS, INC.
DCTH
0001623082
SALAMON STEVEN A J
15 WELLESLEY STREET WEST, SUITE 326
TORONTO
A6
M4Y 0G7
ONTARIO, CANADA
1
0
0
0
0
Tranche B warrants to purchase F-4 Preferred Stock
1000
2024-10-30
4
M
0
500
1000
A
2023-03-29
F-4 PREFERRED STOCK
500
0
I
By Rosalind Advisors, Inc., the advisor to the Rosalind Funds
8% CONVERTIBLE NOTE
0
2024-10-30
4
H
0
0
0
A
CASH
1423333
0
I
By Rosalind Advisors, Inc., the advisor to the Rosalind Funds
Immediately exercisable
The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024.
Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
N/A
Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333.
Steven Salamon
2024-11-01